The world of drug development is changing, and China’s booming biotechnology industry is a big part of that. Over the last ten years, the Chinese government has been working to improve the country’s ability to make medicines. This has led to many new Chinese companies and research centers that can compete with major U.S. hubs like Boston and San Francisco. These Chinese startups can work faster than their U.S. counterparts because of lower costs and fewer regulations. As a result, there are now many new drugs in development. While some of these are improved versions of existing medicines, more and more are completely new and innovative, challenging the U.S.’s long-standing lead in biotechnology. Big pharmaceutical companies and investors have noticed this shift. Many are now licensing experimental drugs from China to add to their own portfolios or to create new biotech companies. This trend has picked up speed in recent years, with a record number of licensing agreements in 2025. According to analysts, one-third of the industry’s licensing spending this year has been on drugs developed in China. These deals give us important information about the types of medicines that drugmakers and investors are interested in. We are tracking these 2025 deals where Chinese drugmakers have licensed their drugs to U.S. and European companies. Our database includes details about the companies involved, the financial terms of their agreements, and information about the medicines and their targets. If we’ve missed any deals or if you have more information to share, please let us know. You can find the database and our methodology here. The database includes deals announced in 2025 where a Chinese biotechnology firm has licensed a drug or drugs to biopharmaceutical companies in the U.S. or Europe. For this database, BioPharma Dive gathered deals announced in 2025 where Chinese drugmakers licensed innovative human medicines to biotech or pharmaceutical companies in the U.S. or Europe. We found these deals in company press releases, analyst reports, and on social media sites like LinkedIn. We excluded deals that didn’t meet our criteria, such as alliances that didn’t mention any specific drug candidates or partnerships between two Chinese companies. We also left out deals involving generic drugs or biosimilars. We usually used a deal’s most advanced program to determine the therapeutic area of focus, treatment type, and stage of development at the time of the deal’s announcement. We categorized the phase of development by the latest stage underway at the time of the deal. Therapeutic areas cover a large number of diseases and sometimes overlap. In most cases, when companies identified more than one therapeutic area with equal priority, we classified them as working on ‘multiple’ therapeutic areas. Companies that identified multiple areas but prioritized one over others were classified under that priority area. Ned Pagliarulo contributed reporting.